(Q37782262)

23 August 2017

title

Malignancy after renal transplantation: the role of immunosuppression (English)

1 reference

23 August 2017

1 reference

Inés Rama

1

0 references

author name string

Josep M Grinyó

series ordinal

2

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

Nature Reviews Nephrology

23 August 2017

published in

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

511-519

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2010.102

23 August 2017

exact match

0 references

cites work

Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Epstein-Barr virus (EBV) nuclear antigen (EBNA)-4 mutation in EBV-associated malignancies in three different populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Impact of cadaveric renal transplantation on survival in patients listed for transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

The changing causes of graft loss and death after kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Causes of death after renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Malignant melanoma in organ allograft recipients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Cancer risk in patients on dialysis and after renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Cancer risk following organ transplantation: a nationwide cohort study in Sweden

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Cancer after kidney transplantation in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Skin cancer in heart transplant recipients: frequency and risk factor analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Cancer mortality in kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Incidence of cancer after kidney transplant: results from the North Italy transplant program

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Predicting risk of nonmelanoma skin cancer and premalignant skin lesions in renal transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Cutaneous melanoma is related to immune suppression in kidney transplant recipients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Outcomes of melanoma in recipients of solid organ transplant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Racial and ethnic variations in incidence and pattern of malignancies after kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

The impact of preexisting or acquired Kaposi sarcoma herpesvirus infection in kidney transplant recipients on morbidity and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Malignancy incidence after renal transplantation in children: a 20-year single-centre experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Merkel's cell carcinoma in organ recipients: report of 41 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Increased incidence of squamous cell carcinoma of eye after kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Cancers complicating organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Primary lung carcinoma after heart or lung transplantation: management and outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Neoplastic disease after heart transplantation: single center experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Carcinoma of the lung after heart transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Malignancy in renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Lymphomas after solid organ transplantation: a collaborative transplant study report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Rapamycin is an effective inhibitor of human renal cancer metastasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Skin cancers after transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Cytokine signaling and Epstein-Barr virus-mediated cell transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Transcription program of human herpesvirus 8 (kaposi's sarcoma-associated herpesvirus).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Death effector domain-containing herpesvirus and poxvirus proteins inhibit both Fas- and TNFR1-induced apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Kaposi sarcoma-associated viral cyclin K overrides cell growth inhibition mediated by oncostatin M through STAT3 inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Serologic association of human herpesvirus eight with posttransplant Kaposi's sarcoma in Saudi Arabia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Outcome of kidney transplant recipients with previous human herpesvirus-8 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Kaposi's sarcoma associated with previous human herpesvirus 8 infection in kidney transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Transmission of human herpesvirus 8 infection from renal-transplant donors to recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Cancer in patients on dialysis for end-stage renal disease: an international collaborative study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Management of solid tumours in organ-transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

KDIGO clinical practice guideline for the care of kidney transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

A prospective study of the incidence of skin cancer and its risk factors in a Spanish Mediterranean population of kidney transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Managing cancer risk and decision making after kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Monitoring of Epstein-Barr virus load and antibody in pediatric renal transplant patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Minimizing the risk of posttransplant malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

The role of mTOR inhibitors in the management of posttransplant malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.102

Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression

31 March 2020

1 reference

12 December 2020

Immunosuppressants and skin cancer in transplant patients: focus on rapamycin

1 reference

12 December 2020

Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center

1 reference

12 December 2020

Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up

1 reference

12 December 2020

Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus.

1 reference

12 December 2020

Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy.

1 reference

12 December 2020

The evaluation of renal transplantation candidates: clinical practice guidelines

1 reference

12 December 2020

Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-II.

1 reference

12 December 2020

Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas

1 reference

12 December 2020

HHV8 in renal transplant recipients

1 reference

12 December 2020

European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment

1 reference

12 December 2020

More on B-cell-depleting induction therapy and acute cellular rejection

1 reference

12 December 2020

The effect of immunosuppression on pre-existing cancers

1 reference

12 December 2020

Incidence and treatment of neoplasia after transplantation

1 reference

12 December 2020

Survival improvement among patients with end-stage renal disease: trends over time for transplant recipients and wait-listed patients.

1 reference

12 December 2020

Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States.

1 reference

12 December 2020

The evaluation of renal transplant candidates: clinical practice guidelines. Patient Care and Education Committee of the American Society of Transplant Physicians.

1 reference

12 December 2020

Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice

1 reference

12 December 2020

Donor transmitted malignancies

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2010.102

1 reference

Dimensions Publication ID

23 August 2017

1024565230

0 references

1 reference